Health News

ZIOPHARM Oncology, Inc., announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin™ or ZIO-301) in the treatment of metastatic breast cancer.

Read more

Filed under: Pharmacy News
Tags: Breast Cancer, cancer, Oncology, Pharmacy

Related posts

• US Oncology Research Network Participates In Phase III Follow-up Study To BiPar’s Investigational Cancer Drug BSI-201 (0)
  US Oncology, Inc. today announced that US Oncology Research will participate in the BiPar Sciences' Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer. Joyce O'Shaughnessy, M.D. Read more [tags] Pharmacy News [/tags]
  
  
• Top-line results from Lymphoseek NEO3-09 Phase 3 study in breast cancer, melanoma (0)
  Neoprobe Corporation, a diversified developer of innovative oncology diagnostic products, today announced top-line results from its Lymphoseek NEO3-09 study. Read more [tags] Pharmacy News [/tags]
  
  
• Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer (0)
  Early trials using targeted monoclonal antibodies in combination with existing therapies show promise in treating pancreatic cancer and metastatic breast cancer, according to research that will be presented by investigators from the University of Pennsylvania's Abramson Cancer Center at the 2010 meeting of the American Society of Clinical Oncology June 4 through 8. Read more [tags] Pharmacy [...]
  
  
• Syndax raises $6 million to support ENCORE 301 study in breast cancer (0)
  Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities [...]
  
  
• Syndax Pharmaceuticals’ Entinostat In Combination Shows Activity In Breast Cancer (0)
  Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer... Read more [tags] Pharmacy News [/tags]